dual gip glp 1 receptor agonists Efficacy and safety of LY3298176, a novel and GLP-1 agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial JCI Insight - Tirzepatide is

Proc Natl Acad Sci 101:37803785

The overall effect represents a systemic move toward regeneration

BPC-157 retains biological activity when administered orally via gavage in rodent studies, which is attributed to its remarkable stability in gastric juice

This single compound can reduce inflammation and oxidative stress, speed the healing of tendons and ligaments, support nerve repair and even improve gut integrity

Understanding your individual response patterns helps you refine protocols over time

Retatrutide (LY3437943) is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) studied for obesity and metabolic outcomes